nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—ADORA2A—Pentoxifylline—systemic scleroderma	0.771	1	CbGbCtD
Vidarabine—DPP4—blood vessel—systemic scleroderma	0.00484	0.151	CbGeAlD
Vidarabine—ADA—connective tissue—systemic scleroderma	0.00314	0.098	CbGeAlD
Vidarabine—Glucosamine—MMP9—systemic scleroderma	0.00254	1	CrCbGaD
Vidarabine—DPP4—connective tissue—systemic scleroderma	0.00248	0.0776	CbGeAlD
Vidarabine—ADK—smooth muscle tissue—systemic scleroderma	0.00234	0.0732	CbGeAlD
Vidarabine—ADK—skin of body—systemic scleroderma	0.00231	0.0723	CbGeAlD
Vidarabine—DPP4—smooth muscle tissue—systemic scleroderma	0.00227	0.071	CbGeAlD
Vidarabine—ADA—digestive system—systemic scleroderma	0.00226	0.0708	CbGeAlD
Vidarabine—ADA—tendon—systemic scleroderma	0.00216	0.0673	CbGeAlD
Vidarabine—ADA—lung—systemic scleroderma	0.00189	0.0591	CbGeAlD
Vidarabine—DPP4—digestive system—systemic scleroderma	0.00179	0.0561	CbGeAlD
Vidarabine—ADK—tendon—systemic scleroderma	0.00176	0.055	CbGeAlD
Vidarabine—DPP4—tendon—systemic scleroderma	0.00171	0.0533	CbGeAlD
Vidarabine—ADK—lung—systemic scleroderma	0.00155	0.0483	CbGeAlD
Vidarabine—DPP4—lung—systemic scleroderma	0.0015	0.0468	CbGeAlD
Vidarabine—Anaphylactic shock—Captopril—systemic scleroderma	0.000498	0.00256	CcSEcCtD
Vidarabine—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.000497	0.00255	CcSEcCtD
Vidarabine—Dysgeusia—Leflunomide—systemic scleroderma	0.000492	0.00253	CcSEcCtD
Vidarabine—Arrhythmia—Mycophenolic acid—systemic scleroderma	0.000492	0.00253	CcSEcCtD
Vidarabine—Shock—Captopril—systemic scleroderma	0.00049	0.00252	CcSEcCtD
Vidarabine—Back pain—Leflunomide—systemic scleroderma	0.000486	0.0025	CcSEcCtD
Vidarabine—Tachycardia—Captopril—systemic scleroderma	0.000486	0.0025	CcSEcCtD
Vidarabine—Pain—Mometasone—systemic scleroderma	0.000485	0.00249	CcSEcCtD
Vidarabine—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.000484	0.00249	CcSEcCtD
Vidarabine—Acute coronary syndrome—Mycophenolate mofetil—systemic scleroderma	0.000478	0.00245	CcSEcCtD
Vidarabine—Myocardial infarction—Mycophenolate mofetil—systemic scleroderma	0.000475	0.00244	CcSEcCtD
Vidarabine—Vision blurred—Leflunomide—systemic scleroderma	0.000474	0.00243	CcSEcCtD
Vidarabine—Asthenia—Pentoxifylline—systemic scleroderma	0.000471	0.00242	CcSEcCtD
Vidarabine—Tension—Mycophenolic acid—systemic scleroderma	0.000471	0.00242	CcSEcCtD
Vidarabine—Nervousness—Mycophenolic acid—systemic scleroderma	0.000466	0.00239	CcSEcCtD
Vidarabine—Hypotension—Captopril—systemic scleroderma	0.000465	0.00239	CcSEcCtD
Vidarabine—Sweating—Mycophenolate mofetil—systemic scleroderma	0.000464	0.00239	CcSEcCtD
Vidarabine—Back pain—Mycophenolic acid—systemic scleroderma	0.000464	0.00238	CcSEcCtD
Vidarabine—Tinnitus—Lisinopril—systemic scleroderma	0.000463	0.00238	CcSEcCtD
Vidarabine—Flushing—Lisinopril—systemic scleroderma	0.000461	0.00237	CcSEcCtD
Vidarabine—Angioedema—Leflunomide—systemic scleroderma	0.000459	0.00236	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.000454	0.00233	CcSEcCtD
Vidarabine—Vision blurred—Mycophenolic acid—systemic scleroderma	0.000452	0.00232	CcSEcCtD
Vidarabine—Tremor—Mycophenolic acid—systemic scleroderma	0.000449	0.00231	CcSEcCtD
Vidarabine—Discomfort—Azathioprine—systemic scleroderma	0.000448	0.0023	CcSEcCtD
Vidarabine—Mediastinal disorder—Lisinopril—systemic scleroderma	0.000447	0.0023	CcSEcCtD
Vidarabine—Paraesthesia—Captopril—systemic scleroderma	0.000447	0.0023	CcSEcCtD
Vidarabine—Palpitations—Leflunomide—systemic scleroderma	0.000444	0.00228	CcSEcCtD
Vidarabine—Dyspnoea—Captopril—systemic scleroderma	0.000444	0.00228	CcSEcCtD
Vidarabine—Arrhythmia—Lisinopril—systemic scleroderma	0.000443	0.00228	CcSEcCtD
Vidarabine—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.000443	0.00227	CcSEcCtD
Vidarabine—Somnolence—Captopril—systemic scleroderma	0.000443	0.00227	CcSEcCtD
Vidarabine—Agitation—Mycophenolic acid—systemic scleroderma	0.000441	0.00226	CcSEcCtD
Vidarabine—Cough—Leflunomide—systemic scleroderma	0.000439	0.00225	CcSEcCtD
Vidarabine—Cardiac failure—Prednisone—systemic scleroderma	0.000437	0.00224	CcSEcCtD
Vidarabine—Dizziness—Pentoxifylline—systemic scleroderma	0.000434	0.00223	CcSEcCtD
Vidarabine—Hypertension—Leflunomide—systemic scleroderma	0.000434	0.00223	CcSEcCtD
Vidarabine—Hypoaesthesia—Mycophenolate mofetil—systemic scleroderma	0.000433	0.00222	CcSEcCtD
Vidarabine—Syncope—Mycophenolic acid—systemic scleroderma	0.00043	0.00221	CcSEcCtD
Vidarabine—Chest pain—Leflunomide—systemic scleroderma	0.000428	0.0022	CcSEcCtD
Vidarabine—Anxiety—Leflunomide—systemic scleroderma	0.000427	0.00219	CcSEcCtD
Vidarabine—Tension—Lisinopril—systemic scleroderma	0.000424	0.00218	CcSEcCtD
Vidarabine—Palpitations—Mycophenolic acid—systemic scleroderma	0.000424	0.00218	CcSEcCtD
Vidarabine—Dysgeusia—Lisinopril—systemic scleroderma	0.000423	0.00217	CcSEcCtD
Vidarabine—Discomfort—Leflunomide—systemic scleroderma	0.000423	0.00217	CcSEcCtD
Vidarabine—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.000422	0.00217	CcSEcCtD
Vidarabine—Nervousness—Lisinopril—systemic scleroderma	0.00042	0.00216	CcSEcCtD
Vidarabine—Affect lability—Prednisone—systemic scleroderma	0.000419	0.00215	CcSEcCtD
Vidarabine—Dry mouth—Leflunomide—systemic scleroderma	0.000419	0.00215	CcSEcCtD
Vidarabine—Cough—Mycophenolic acid—systemic scleroderma	0.000419	0.00215	CcSEcCtD
Vidarabine—Back pain—Lisinopril—systemic scleroderma	0.000418	0.00215	CcSEcCtD
Vidarabine—Vomiting—Pentoxifylline—systemic scleroderma	0.000418	0.00215	CcSEcCtD
Vidarabine—Convulsion—Mycophenolic acid—systemic scleroderma	0.000416	0.00213	CcSEcCtD
Vidarabine—Rash—Pentoxifylline—systemic scleroderma	0.000414	0.00213	CcSEcCtD
Vidarabine—Hypertension—Mycophenolic acid—systemic scleroderma	0.000414	0.00213	CcSEcCtD
Vidarabine—Dermatitis—Pentoxifylline—systemic scleroderma	0.000414	0.00213	CcSEcCtD
Vidarabine—Headache—Pentoxifylline—systemic scleroderma	0.000412	0.00211	CcSEcCtD
Vidarabine—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00041	0.00211	CcSEcCtD
Vidarabine—Chest pain—Mycophenolic acid—systemic scleroderma	0.000408	0.0021	CcSEcCtD
Vidarabine—Vision blurred—Lisinopril—systemic scleroderma	0.000407	0.00209	CcSEcCtD
Vidarabine—Anxiety—Mycophenolic acid—systemic scleroderma	0.000407	0.00209	CcSEcCtD
Vidarabine—Asthenia—Mometasone—systemic scleroderma	0.000407	0.00209	CcSEcCtD
Vidarabine—Hypotension—Azathioprine—systemic scleroderma	0.000406	0.00209	CcSEcCtD
Vidarabine—Tinnitus—Mycophenolate mofetil—systemic scleroderma	0.000405	0.00208	CcSEcCtD
Vidarabine—Cardiac arrest—Prednisone—systemic scleroderma	0.000405	0.00208	CcSEcCtD
Vidarabine—Tremor—Lisinopril—systemic scleroderma	0.000405	0.00208	CcSEcCtD
Vidarabine—Mood swings—Prednisone—systemic scleroderma	0.000404	0.00207	CcSEcCtD
Vidarabine—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000404	0.00207	CcSEcCtD
Vidarabine—Discomfort—Mycophenolic acid—systemic scleroderma	0.000404	0.00207	CcSEcCtD
Vidarabine—Tachycardia—Leflunomide—systemic scleroderma	0.000401	0.00206	CcSEcCtD
Vidarabine—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000399	0.00205	CcSEcCtD
Vidarabine—Hyperhidrosis—Leflunomide—systemic scleroderma	0.000397	0.00204	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000396	0.00203	CcSEcCtD
Vidarabine—Angioedema—Lisinopril—systemic scleroderma	0.000395	0.00203	CcSEcCtD
Vidarabine—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000392	0.00201	CcSEcCtD
Vidarabine—Nausea—Pentoxifylline—systemic scleroderma	0.00039	0.002	CcSEcCtD
Vidarabine—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.000389	0.002	CcSEcCtD
Vidarabine—Syncope—Lisinopril—systemic scleroderma	0.000387	0.00199	CcSEcCtD
Vidarabine—Shock—Mycophenolic acid—systemic scleroderma	0.000385	0.00198	CcSEcCtD
Vidarabine—Hypotension—Leflunomide—systemic scleroderma	0.000383	0.00197	CcSEcCtD
Vidarabine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000382	0.00196	CcSEcCtD
Vidarabine—Palpitations—Lisinopril—systemic scleroderma	0.000382	0.00196	CcSEcCtD
Vidarabine—Loss of consciousness—Lisinopril—systemic scleroderma	0.00038	0.00195	CcSEcCtD
Vidarabine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000378	0.00194	CcSEcCtD
Vidarabine—Cough—Lisinopril—systemic scleroderma	0.000377	0.00194	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000374	0.00192	CcSEcCtD
Vidarabine—Tension—Mycophenolate mofetil—systemic scleroderma	0.000372	0.00191	CcSEcCtD
Vidarabine—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000371	0.0019	CcSEcCtD
Vidarabine—Paraesthesia—Leflunomide—systemic scleroderma	0.000369	0.00189	CcSEcCtD
Vidarabine—Chest pain—Lisinopril—systemic scleroderma	0.000368	0.00189	CcSEcCtD
Vidarabine—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.000368	0.00189	CcSEcCtD
Vidarabine—Anxiety—Lisinopril—systemic scleroderma	0.000367	0.00188	CcSEcCtD
Vidarabine—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000366	0.00188	CcSEcCtD
Vidarabine—Dyspnoea—Leflunomide—systemic scleroderma	0.000366	0.00188	CcSEcCtD
Vidarabine—Hypotension—Mycophenolic acid—systemic scleroderma	0.000366	0.00188	CcSEcCtD
Vidarabine—Discomfort—Lisinopril—systemic scleroderma	0.000363	0.00187	CcSEcCtD
Vidarabine—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.000363	0.00187	CcSEcCtD
Vidarabine—Vomiting—Mometasone—systemic scleroderma	0.00036	0.00185	CcSEcCtD
Vidarabine—Dry mouth—Lisinopril—systemic scleroderma	0.00036	0.00185	CcSEcCtD
Vidarabine—Rash—Mometasone—systemic scleroderma	0.000357	0.00184	CcSEcCtD
Vidarabine—Asthenia—Captopril—systemic scleroderma	0.000357	0.00184	CcSEcCtD
Vidarabine—Dermatitis—Mometasone—systemic scleroderma	0.000357	0.00183	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000357	0.00183	CcSEcCtD
Vidarabine—Headache—Mometasone—systemic scleroderma	0.000355	0.00182	CcSEcCtD
Vidarabine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000355	0.00182	CcSEcCtD
Vidarabine—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000353	0.00181	CcSEcCtD
Vidarabine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000352	0.00181	CcSEcCtD
Vidarabine—Pain—Leflunomide—systemic scleroderma	0.000351	0.0018	CcSEcCtD
Vidarabine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000349	0.00179	CcSEcCtD
Vidarabine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000348	0.00179	CcSEcCtD
Vidarabine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000348	0.00179	CcSEcCtD
Vidarabine—Shock—Lisinopril—systemic scleroderma	0.000347	0.00178	CcSEcCtD
Vidarabine—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000346	0.00178	CcSEcCtD
Vidarabine—Tachycardia—Lisinopril—systemic scleroderma	0.000344	0.00177	CcSEcCtD
Vidarabine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000341	0.00175	CcSEcCtD
Vidarabine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00034	0.00174	CcSEcCtD
Vidarabine—Mood swings—Methotrexate—systemic scleroderma	0.000337	0.00173	CcSEcCtD
Vidarabine—Nausea—Mometasone—systemic scleroderma	0.000337	0.00173	CcSEcCtD
Vidarabine—Pain—Mycophenolic acid—systemic scleroderma	0.000335	0.00172	CcSEcCtD
Vidarabine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000335	0.00172	CcSEcCtD
Vidarabine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000333	0.00171	CcSEcCtD
Vidarabine—Cough—Mycophenolate mofetil—systemic scleroderma	0.00033	0.0017	CcSEcCtD
Vidarabine—Hypotension—Lisinopril—systemic scleroderma	0.00033	0.00169	CcSEcCtD
Vidarabine—Dizziness—Captopril—systemic scleroderma	0.000329	0.00169	CcSEcCtD
Vidarabine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000328	0.00168	CcSEcCtD
Vidarabine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000327	0.00168	CcSEcCtD
Vidarabine—Urticaria—Leflunomide—systemic scleroderma	0.000326	0.00167	CcSEcCtD
Vidarabine—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000324	0.00166	CcSEcCtD
Vidarabine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000322	0.00166	CcSEcCtD
Vidarabine—Myocardial infarction—Prednisone—systemic scleroderma	0.000322	0.00165	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000321	0.00165	CcSEcCtD
Vidarabine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000321	0.00165	CcSEcCtD
Vidarabine—Hypersensitivity—Azathioprine—systemic scleroderma	0.00032	0.00164	CcSEcCtD
Vidarabine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000318	0.00164	CcSEcCtD
Vidarabine—Paraesthesia—Lisinopril—systemic scleroderma	0.000317	0.00163	CcSEcCtD
Vidarabine—Vomiting—Captopril—systemic scleroderma	0.000317	0.00163	CcSEcCtD
Vidarabine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000315	0.00162	CcSEcCtD
Vidarabine—Dyspnoea—Lisinopril—systemic scleroderma	0.000314	0.00161	CcSEcCtD
Vidarabine—Rash—Captopril—systemic scleroderma	0.000314	0.00161	CcSEcCtD
Vidarabine—Dermatitis—Captopril—systemic scleroderma	0.000314	0.00161	CcSEcCtD
Vidarabine—Somnolence—Lisinopril—systemic scleroderma	0.000313	0.00161	CcSEcCtD
Vidarabine—Headache—Captopril—systemic scleroderma	0.000312	0.0016	CcSEcCtD
Vidarabine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000309	0.00159	CcSEcCtD
Vidarabine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000304	0.00156	CcSEcCtD
Vidarabine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000302	0.00155	CcSEcCtD
Vidarabine—Pain—Lisinopril—systemic scleroderma	0.000302	0.00155	CcSEcCtD
Vidarabine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000302	0.00155	CcSEcCtD
Vidarabine—Bradycardia—Prednisone—systemic scleroderma	0.0003	0.00154	CcSEcCtD
Vidarabine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000299	0.00153	CcSEcCtD
Vidarabine—Nausea—Captopril—systemic scleroderma	0.000296	0.00152	CcSEcCtD
Vidarabine—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000295	0.00152	CcSEcCtD
Vidarabine—Asthenia—Leflunomide—systemic scleroderma	0.000294	0.00151	CcSEcCtD
Vidarabine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000289	0.00148	CcSEcCtD
Vidarabine—Dizziness—Azathioprine—systemic scleroderma	0.000287	0.00148	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000282	0.00145	CcSEcCtD
Vidarabine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000281	0.00144	CcSEcCtD
Vidarabine—Urticaria—Lisinopril—systemic scleroderma	0.00028	0.00144	CcSEcCtD
Vidarabine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000277	0.00143	CcSEcCtD
Vidarabine—Vomiting—Azathioprine—systemic scleroderma	0.000276	0.00142	CcSEcCtD
Vidarabine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000275	0.00141	CcSEcCtD
Vidarabine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000275	0.00141	CcSEcCtD
Vidarabine—Drowsiness—Methotrexate—systemic scleroderma	0.000274	0.00141	CcSEcCtD
Vidarabine—Rash—Azathioprine—systemic scleroderma	0.000274	0.00141	CcSEcCtD
Vidarabine—Dermatitis—Azathioprine—systemic scleroderma	0.000274	0.00141	CcSEcCtD
Vidarabine—Flushing—Prednisone—systemic scleroderma	0.000274	0.00141	CcSEcCtD
Vidarabine—Headache—Azathioprine—systemic scleroderma	0.000272	0.0014	CcSEcCtD
Vidarabine—Dizziness—Leflunomide—systemic scleroderma	0.000271	0.00139	CcSEcCtD
Vidarabine—Pain—Mycophenolate mofetil—systemic scleroderma	0.000264	0.00136	CcSEcCtD
Vidarabine—Arrhythmia—Prednisone—systemic scleroderma	0.000263	0.00135	CcSEcCtD
Vidarabine—Sweating—Methotrexate—systemic scleroderma	0.000263	0.00135	CcSEcCtD
Vidarabine—Vomiting—Leflunomide—systemic scleroderma	0.000261	0.00134	CcSEcCtD
Vidarabine—Hypersensitivity—Lisinopril—systemic scleroderma	0.00026	0.00133	CcSEcCtD
Vidarabine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000259	0.00133	CcSEcCtD
Vidarabine—Rash—Leflunomide—systemic scleroderma	0.000259	0.00133	CcSEcCtD
Vidarabine—Dermatitis—Leflunomide—systemic scleroderma	0.000259	0.00133	CcSEcCtD
Vidarabine—Nausea—Azathioprine—systemic scleroderma	0.000258	0.00133	CcSEcCtD
Vidarabine—Headache—Leflunomide—systemic scleroderma	0.000257	0.00132	CcSEcCtD
Vidarabine—Asthenia—Lisinopril—systemic scleroderma	0.000253	0.0013	CcSEcCtD
Vidarabine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000249	0.00128	CcSEcCtD
Vidarabine—Rash—Mycophenolic acid—systemic scleroderma	0.000247	0.00127	CcSEcCtD
Vidarabine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000247	0.00127	CcSEcCtD
Vidarabine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000245	0.00126	CcSEcCtD
Vidarabine—Headache—Mycophenolic acid—systemic scleroderma	0.000245	0.00126	CcSEcCtD
Vidarabine—Nausea—Leflunomide—systemic scleroderma	0.000244	0.00125	CcSEcCtD
Vidarabine—Vision blurred—Prednisone—systemic scleroderma	0.000242	0.00124	CcSEcCtD
Vidarabine—Agitation—Prednisone—systemic scleroderma	0.000236	0.00121	CcSEcCtD
Vidarabine—Angioedema—Prednisone—systemic scleroderma	0.000234	0.0012	CcSEcCtD
Vidarabine—Dizziness—Lisinopril—systemic scleroderma	0.000233	0.0012	CcSEcCtD
Vidarabine—Nausea—Mycophenolic acid—systemic scleroderma	0.000233	0.00119	CcSEcCtD
Vidarabine—Syncope—Prednisone—systemic scleroderma	0.00023	0.00118	CcSEcCtD
Vidarabine—Tinnitus—Methotrexate—systemic scleroderma	0.00023	0.00118	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—systemic scleroderma	0.000229	0.00117	CcSEcCtD
Vidarabine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000228	0.00117	CcSEcCtD
Vidarabine—Loss of consciousness—Prednisone—systemic scleroderma	0.000226	0.00116	CcSEcCtD
Vidarabine—Vomiting—Lisinopril—systemic scleroderma	0.000224	0.00115	CcSEcCtD
Vidarabine—Rash—Lisinopril—systemic scleroderma	0.000222	0.00114	CcSEcCtD
Vidarabine—Convulsion—Prednisone—systemic scleroderma	0.000222	0.00114	CcSEcCtD
Vidarabine—Dermatitis—Lisinopril—systemic scleroderma	0.000222	0.00114	CcSEcCtD
Vidarabine—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000222	0.00114	CcSEcCtD
Vidarabine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000222	0.00114	CcSEcCtD
Vidarabine—Hypertension—Prednisone—systemic scleroderma	0.000222	0.00114	CcSEcCtD
Vidarabine—Headache—Lisinopril—systemic scleroderma	0.000221	0.00113	CcSEcCtD
Vidarabine—Anxiety—Prednisone—systemic scleroderma	0.000218	0.00112	CcSEcCtD
Vidarabine—Discomfort—Prednisone—systemic scleroderma	0.000216	0.00111	CcSEcCtD
Vidarabine—Dysgeusia—Methotrexate—systemic scleroderma	0.00021	0.00108	CcSEcCtD
Vidarabine—Nausea—Lisinopril—systemic scleroderma	0.000209	0.00108	CcSEcCtD
Vidarabine—Anaphylactic shock—Prednisone—systemic scleroderma	0.000209	0.00108	CcSEcCtD
Vidarabine—Back pain—Methotrexate—systemic scleroderma	0.000207	0.00107	CcSEcCtD
Vidarabine—Shock—Prednisone—systemic scleroderma	0.000206	0.00106	CcSEcCtD
Vidarabine—Tachycardia—Prednisone—systemic scleroderma	0.000204	0.00105	CcSEcCtD
Vidarabine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000204	0.00105	CcSEcCtD
Vidarabine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000202	0.00104	CcSEcCtD
Vidarabine—Vision blurred—Methotrexate—systemic scleroderma	0.000202	0.00104	CcSEcCtD
Vidarabine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000196	0.00101	CcSEcCtD
Vidarabine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000195	0.001	CcSEcCtD
Vidarabine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000195	0.001	CcSEcCtD
Vidarabine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000194	0.000994	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000191	0.00098	CcSEcCtD
Vidarabine—Paraesthesia—Prednisone—systemic scleroderma	0.000188	0.000966	CcSEcCtD
Vidarabine—Cough—Methotrexate—systemic scleroderma	0.000187	0.000961	CcSEcCtD
Vidarabine—Convulsion—Methotrexate—systemic scleroderma	0.000186	0.000954	CcSEcCtD
Vidarabine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000184	0.000943	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—systemic scleroderma	0.000183	0.000938	CcSEcCtD
Vidarabine—Discomfort—Methotrexate—systemic scleroderma	0.00018	0.000927	CcSEcCtD
Vidarabine—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000175	0.000899	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000169	0.000869	CcSEcCtD
Vidarabine—Urticaria—Prednisone—systemic scleroderma	0.000166	0.000855	CcSEcCtD
Vidarabine—Hypotension—Methotrexate—systemic scleroderma	0.000164	0.00084	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000159	0.000819	CcSEcCtD
Vidarabine—Paraesthesia—Methotrexate—systemic scleroderma	0.000157	0.000807	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—systemic scleroderma	0.000156	0.000802	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—systemic scleroderma	0.000156	0.000799	CcSEcCtD
Vidarabine—Hypersensitivity—Prednisone—systemic scleroderma	0.000154	0.000793	CcSEcCtD
Vidarabine—Asthenia—Prednisone—systemic scleroderma	0.00015	0.000772	CcSEcCtD
Vidarabine—Pain—Methotrexate—systemic scleroderma	0.00015	0.000769	CcSEcCtD
Vidarabine—Urticaria—Methotrexate—systemic scleroderma	0.000139	0.000714	CcSEcCtD
Vidarabine—Dizziness—Prednisone—systemic scleroderma	0.000138	0.000711	CcSEcCtD
Vidarabine—Vomiting—Prednisone—systemic scleroderma	0.000133	0.000684	CcSEcCtD
Vidarabine—Rash—Prednisone—systemic scleroderma	0.000132	0.000678	CcSEcCtD
Vidarabine—Dermatitis—Prednisone—systemic scleroderma	0.000132	0.000678	CcSEcCtD
Vidarabine—Headache—Prednisone—systemic scleroderma	0.000131	0.000674	CcSEcCtD
Vidarabine—Hypersensitivity—Methotrexate—systemic scleroderma	0.000129	0.000662	CcSEcCtD
Vidarabine—Asthenia—Methotrexate—systemic scleroderma	0.000126	0.000645	CcSEcCtD
Vidarabine—Nausea—Prednisone—systemic scleroderma	0.000124	0.000639	CcSEcCtD
Vidarabine—Dizziness—Methotrexate—systemic scleroderma	0.000116	0.000595	CcSEcCtD
Vidarabine—Vomiting—Methotrexate—systemic scleroderma	0.000111	0.000572	CcSEcCtD
Vidarabine—Rash—Methotrexate—systemic scleroderma	0.00011	0.000567	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—systemic scleroderma	0.00011	0.000566	CcSEcCtD
Vidarabine—Headache—Methotrexate—systemic scleroderma	0.00011	0.000563	CcSEcCtD
Vidarabine—Nausea—Methotrexate—systemic scleroderma	0.000104	0.000534	CcSEcCtD
